Related Experiment Video
Updated: May 21, 2026
07:18
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
Published on: June 13, 2019
Endosialin expression in side populations in human sarcoma cell lines.
Cecile Rouleau1, Jose Sancho, Juanita Campos-Rivera
1Genzyme Corporation, Framingham, MA 01701, USA.
Oncology Letters
|June 29, 2012
Summary
This study reveals endosialin (CD248) is expressed in sarcoma side population (SP) cells, which possess stem cell-like properties. This finding suggests endosialin is a potential therapeutic target for treating sarcomas.
Area of Science:
- Oncology
- Cancer Stem Cell Biology
- Molecular Oncology
Background:
- Side population (SP) cells exhibit stem cell-like properties and are found in various cancers, including sarcomas.
- SP cells isolated from tumors often display high malignant potential.
- The molecular characteristics of sarcoma SP cells remain largely unexplored.
Purpose of the Study:
- To investigate endosialin (CD248) as a potential therapeutic target in sarcomas.
- To determine the expression of endosialin in sarcoma side population (SP) cells.
Main Methods:
- Utilized the Hoechst 33342 exclusion side population (SP) assay.
- Employed flow cytometry for cell analysis.
- Examined six human sarcoma cell lines: fibrosarcoma (HT-1080), osteosarcoma (SJSA-1, HOS), and Ewing sarcoma (A-673, SK-ES-1).
Main Results:
- Endosialin (CD248) expression was detected in sarcoma side population (SP) cells for the first time.
- Confirmed endosialin as a marker expressed on sarcoma SP cells.
- Demonstrated the presence of endosialin in multiple sarcoma subtypes.
Conclusions:
- Endosialin is expressed on sarcoma side population (SP) cells.
- These findings support endosialin as a promising therapeutic target for sarcomas.
- Further research into endosialin-targeted therapies for sarcoma is warranted.
